^
Association details:
| Biomarker: | MLL-AFF1 fusion + KRAS mutation |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
Published date:
05/15/2020
Excerpt:
Surprisingly, entospletinib did not decrease leukemia burden in two KMT2A-AFF1 PDX models with NRAS/ or KRAS mutations, suggesting potential RAS-mediated resistance to SYK inhibition.
DOI:
10.3324/haematol.2019.241729
